Brief: Eloxx Pharmaceuticals Granted Extension By Nasdaq To Regain Compliance With The Market Value Of Listed Securities Continued Listing Requirement
06/06/2023 14:15
June 6 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS GRANTED EXTENSION BY NASDAQ TO
REGAIN
COMPLIANCE WITH THE MARKET VALUE OF LISTED SECURITIES CONTINUED
LISTING REQUIREMENT
Source text for Eikon: ID:nGNX1P7ZDv
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome